Traders Sell Alexion Pharmaceuticals (ALXN) on Strength (ALXN)

Investors sold shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on strength during trading hours on Tuesday. $76.55 million flowed into the stock on the tick-up and $139.04 million flowed out of the stock on the tick-down, for a money net flow of $62.49 million out of the stock. Of all stocks tracked, Alexion Pharmaceuticals had the 0th highest net out-flow for the day. Alexion Pharmaceuticals traded up $1.77 for the day and closed at $124.48

ALXN has been the subject of several analyst reports. TheStreet downgraded shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Friday, November 10th. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, December 27th. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 target price for the company in a research note on Tuesday, October 31st. Credit Suisse Group restated a “buy” rating and issued a $166.00 target price on shares of Alexion Pharmaceuticals in a research note on Tuesday, December 12th. Finally, Raymond James Financial restated an “outperform” rating and issued a $130.00 target price (down from $178.00) on shares of Alexion Pharmaceuticals in a research note on Thursday, January 4th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nineteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $153.10.

The stock has a market cap of $27,280.00, a price-to-earnings ratio of 54.52, a PEG ratio of 1.04 and a beta of 1.17. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.32 by $0.12. The firm had revenue of $859.00 million for the quarter, compared to analysts’ expectations of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.23 earnings per share. sell-side analysts forecast that Alexion Pharmaceuticals, Inc. will post 4.82 EPS for the current fiscal year.

In related news, CEO Ludwig Hantson sold 2,553 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total value of $310,521.39. Following the sale, the chief executive officer now directly owns 36,172 shares of the company’s stock, valued at $4,399,600.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.35% of the company’s stock.

Several large investors have recently modified their holdings of the business. Evercore Wealth Management LLC raised its holdings in shares of Alexion Pharmaceuticals by 8.1% during the second quarter. Evercore Wealth Management LLC now owns 1,665 shares of the biopharmaceutical company’s stock worth $202,000 after purchasing an additional 125 shares during the period. Wealthsource Partners LLC raised its holdings in shares of Alexion Pharmaceuticals by 4.4% during the second quarter. Wealthsource Partners LLC now owns 3,002 shares of the biopharmaceutical company’s stock worth $365,000 after purchasing an additional 126 shares during the period. National Asset Management Inc. raised its holdings in shares of Alexion Pharmaceuticals by 5.1% during the second quarter. National Asset Management Inc. now owns 3,345 shares of the biopharmaceutical company’s stock worth $407,000 after purchasing an additional 162 shares during the period. Tudor Investment Corp ET AL raised its holdings in shares of Alexion Pharmaceuticals by 2.4% during the second quarter. Tudor Investment Corp ET AL now owns 7,207 shares of the biopharmaceutical company’s stock worth $877,000 after purchasing an additional 170 shares during the period. Finally, MML Investors Services LLC raised its holdings in shares of Alexion Pharmaceuticals by 4.4% during the second quarter. MML Investors Services LLC now owns 4,563 shares of the biopharmaceutical company’s stock worth $555,000 after purchasing an additional 192 shares during the period. 94.27% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Traders Sell Alexion Pharmaceuticals (ALXN) on Strength (ALXN)” was reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://weekherald.com/2018/01/18/traders-sell-alexion-pharmaceuticals-alxn-on-strength-alxn.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply